Strategic Planning Bureau Director-General

I. Office of Public Relations

Introduction

 The Office of Public Relations has been organized as one branch of the Strategic Planning Bureau Director-General, which was assigned as a public section under the supervision of the president of the National Cancer Center (NCC) in April 2013. A full-time staff member was newly assigned to the Office of Public Relations in April 2014. Our task is to manage the NCC homepage (https://www.ncc.go.jp), publication of reports, coverage and delivery of press conferences and press releases. By sharing the mission and vision between staff members throughout the NCC, we provide information about NCC's most outstanding activities in cancer care, research, screening, prevention, and policy making.

Our team and what we do

During weekly meetings of the Office of Public Relations, we performed a prompt decision making regarding the public relations policy and shared information about our tasks using a TV con-ference system between the Tsukiji and Kashiwa campuses. We received information on the publicity work from each department, and drafted a publication plan. Also, by the distribution of the intramural information for staff members in the NCC, we shared vital messages via e-mail, bulletin board, and/or information magazine to facilitate communication between staff and the executives. We distributed information promptly by publishing and sharing press releases, press conferences, and seminars about novel treatment, research activity and notable accomplishments within the NCC and elsewhere.

• Homepage improvement and updates
• Public information magazine "The National Cancer Center News": for external hospitals, academia, research institutions, and administrative agencies
• Public information magazine "hibiho": for patients in the NCC Hospital (NCCH) and the NCC Hospital East (NCCHE)
• Support for events, seminars, and public information
• Media support at press conferences, press releases, and media coverage

 We held 13 cases of press conferences and published 65 cases of press releases. Moreover, 418 cases of national newspapers (5 major papers), 102 cases of TV (Tokyo key), and 562 cases of others (magazines, local newspapers, etc.) were reported on each media.

Future prospects

 In October 2017, we renewed the NCC homepage into a more attractive, informative, and accessible page for users to inform NCC's activities in cancer care, research, screening, prevention, and policy making. We also feel it is important to move forward public relations activities towards expansion to overseas media via our homepage and press releases. We hope that all staff members in the NCC share their information and thoughts, and will move in the same direction to execute NCC's mission.

Hirokazu Watanabe, Miyako Horikoshi, Reiko Uokawa, Toru Kishida, Yumi Kitada, Syoko Satoh, Naoto Gotohda, Kiyotaka Yoh, Rei Yamagami, Reina Kyo

II. Office of International Affairs

Seiichiro Yamamoto, Sakiko Suzuki, Mitsuko Otani, Kimiko Oka, Kay Ohara

Our team and what we do

 The National Cancer Center (NCC)'s international affairs are mainly promoted through:

1. Personnel exchange with leading medical institutions, nurturing cancer researchers / healthcare professionals, and a global network,
2. Participation in international collaborative cancer research projects, and outreach to the international medical community,
3. Sharing our medical expertise and information with overseas colleagues, with a focus on Asia, thus leading the advancement of cancer care in the region.

 The Office of International Affairs serves as a conduit to, and supports the abovementioned activities.

1. Collaboration with International Agencies and Nurturing Human Resources

 This year, we advanced our relationship with the International Agency for Research on Cancer (IARC) by concluding two memoranda of understanding (MOUs), seconded a pathologist, and had another appointed to the editorial board of the WHO/IARC classification of tumours. Two seminars were co-organized with the IARC. To the US National Cancer Institute (NCI), we despatched an epidemiologist for further research into simulating models, also strengthening our platform for future collaboration. As part of the cancer moonshot initiative, we took part in the US-Japan-Korea trilateral cancer moonshot technical meeting in Seoul, and also concluded another memorandum of collaboration on clinical proteogenomics cancer research with the NCI.

2. Collaborative Medical Research

 The NCC continues its participation in multiple international collaborative research programs and international clinical trials. More details can be found on sections detailing activities of the respective teams.

3. Medical Contribution, with a focus on Asia

 We continue to host medical staff on visiting fellowship visits to our two campuses. In 2017 and the first three months of 2018, we hosted a total of 236 doctors/medical staff long term, in addition to 206 specialists short term (no more than three days). This is also topped off with more visitors including the deputy prime minister of Russia, and health ministers of Singapore and Lithuania.

 Designated as an IARC/GICR Collaborating Centre, we have stepped up our activities to help propagate cancer registration in Asia, co-organizing seminars in Myanmar, Thailand and Indonesia. An MOU was concluded with Dharmais Cancer Hospital, the National Cancer Center of Indonesia in October. We also took part in a Cancer Control Workshop in Beijing, with the national cancer centers of China and Korea, in March 2018.

 On the front for developing early phase drugs, we formed a consortium with leading early phase institutions in Hong Kong, Taiwan, Singapore, and Korea.

Table 1. January 2017 - March 2018 Visiting fellows and Short term (within 3 days) visitors

Table 1. January 2017 - March 2018 Visiting fellows and Short term (within 3 days) visitors(Full Size)

Table 2. January 2017 - March 2018 Visiting fellows (with and without fee) of the Hospital

Table 2. January 2017 - March 2018 Visiting fellows (with and without fee) of the Hospital(Full Size)

Table 3. January 2017 - March 2018 Visiting fellows (with and without fee) of all centers except the Hospital

Table 3. January 2017 - March 2018 Visiting fellows (with and without fee) of all centers except the Hospital(Full Size)

Table 4. January 2017 - March 2018 Short term (within 3 days) visitors of the Hospital (Tsukiji Campus)

Table 4. January 2017 - March 2018 Short term (within 3 days) visitors of the Hospital (Tsukiji Campus)(Full Size)

Table 5. January 2017 - March 2018 Short term (within 3 days) visitors of all centers except the Hospital

Table 5. January 2017 - March 2018 Short term (within 3 days) visitors of all centers except the Hospital(Full Size)

III. Office of Development

Chie Matsuda, Kimiko Oka

What we do

 We receive limited funding from the Japanese Government at around 10% of its total cash inflow.

 Currently, the National Cancer Center's (NCC's) main sources of cash flow are revenues from Medical Service, Cancer Research, and Clinical Trial. It is vital to diversify these revenue sources to make NCC's financial position stable for long-term. As one of alternatives, we look for sustainable growth in donation revenue from NCC supporters.

What we achieved in FY2017

 Donation revenue increased by 23% Year on Year (YoY) to ¥139mm in FY2017, the third consecutive increase since FY2015, with 3% YoY growth in the number of donors. The main factors for the revenue growth are as follows:

1. A major legacy for NCC Cancer Research
2. A major donation from NCC Hospital East (NCCHE) patient for "NEXT Project"
3. Legacies from NCC Hospital (NCCH) patients and families

What we will do - Priorities in FY2018

 We will focus on following measures:

1. To diversify donor's portfolios from NCCH/NCCHE patients and families, companies in the medical sector to all those who support NCC Vision "Don't get cancer, Not beaten by cancer, and Live with cancer", we continue to develop publicities of the reason why we need fund and how the fund is spent.
2. To boost legacy giving for future cancer research from seniors and upper-middle classes who are interested in philanthropy, we attempt to build up long-term partnership with professionals in this area, including trust banks, lawyers, and accountants.

Figure 1. Donation Revenue and the Number of Donors (Yearly)

Figure 1. Donation Revenue and the Number of Donors (Yearly)(Full Size)

Figure 2. Number of Donors, by Designation (FY2017)

Figure 2. Number of Donors, by Designation (FY2017)(Full Size)

Figure 3. Donation Revenue ¥mm, by Designation (FY2017)

Figure 3. Donation Revenue ¥mm, by Designation (FY2017)(Full Size)